Search results
Singapore. At GSK, we unite science, technology and talent to get ahead of disease together. We prevent and treat disease with vaccines, specialty and general medicines investing in four core therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology.
GSK’s latest investment is a strong show of confidence in Singapore’s world-class infrastructure and skilled workforce for biopharmaceutical manufacturing. In addition to efforts in developing manufacturing leaders in Singapore, GSK has also been a steadfast partner to our research ecosystem.
Jul 13, 2023 · SINGAPORE - The expansion of British drugmaker GSK’s facility in Tuas has earned the title of Singapore’s largest vaccine production site based on a cumulative investment of some $850 million,...
Nov 17, 2022 · SINGAPORE - GSK officially opened its first high-potency manufacturing and test facility in Singapore on Thursday, with the capability to manufacture highly potent components for cancer...
Issued: 17 November 2022, Singapore GSK opens first-in-Singapore high potency manufacturing and testing facility for next generation cancer treatments • S$44m investment in the new high potency manufacturing facility and laboratory further strengthens Jurong site capabilities to launch new products more quickly
THE expansion of British drugmaker GSK’s facility at Tuas has earned it the title of Singapore’s largest vaccine production site based on a cumulative investment of some S$850 million, said Minister for Trade and Industry Gan Kim Yong.
The expansion of British drugmaker GSK’s facility at Tuas has earned it the title of Singapore’s largest vaccine production site based on a cumulative investment of some S$850 million, said Minister for Trade and Industry Gan Kim Yong.
Oct 30, 2017 · SINGAPORE - British pharmaceutical giant GSK officially opened its Asia headquarters here on Monday (Oct 30). Called GSK Asia House, the facility in Rochester Park functions as the commercial...
Jun 27, 2024 · A wholly-owned subsidiary of Sembcorp Industries U96 -. has secured long-term power purchase agreements (PPAs) with subsidiaries of global biopharma company GSK. According to a June 27 bourse filing, the subsidiary — Sembcorp Power — will supply up to 10 megawatts (MW) of electricity to all three of GSK’s global manufacturing sites in ...
Nov 17, 2022 · Facility will manufacture a key ingredient for antibody drug conjugates (ADCs) GSK plc today announced the opening of a new, S$44 million high potency facility (HPF) in its strategic New Product Introduction site in Jurong, Singapore.
